Latest News Archive

Please select Category, Year, and then Month to display items

2020 NSFAS Funding at Universities

04 March 2020

What does the bursary cover?

• Accommodation
• Transport (up to 40 km from institution)
• Meal allowance (including incidental allowance)
• Book allowance
• Registration
• Tuition
• Funded students with disabilities need to submit claims for assistive devices and human support directly to the university’s Centre for Universal Access and Disability Support (CUADS)/Financial Aid office.

Who qualifies for NSFAS allowances?

STUDENTS STAYING IN A RESIDENCE:
• Books up to a maximum of R5 200
• Actual accommodation cost
• Meals (including incidental allowance) up to a maximum of R15 000

STUDENTS LIVING OFF CAMPUS IN FAMILY ACCOMMODATION

• Books up to a maximum of R5 200
• Meals (including incidental allowance) up to a maximum of R15 000
• Transport up to a maximum of R7 500

STUDENTS LIVING OFF CAMPUS IN ACCREDITED and NON-ACCREDITED ACCOMMODATION:

• Books up to a maximum of R5 200
• Private accommodation amount to a maximum of R34 400
• Meals (including incidental allowance) up to a maximum of R15 000

DISTANCE-LEARNING STUDENTS:

• Books based on the number of modules registered, up to a maximum of R5 200

Please note that students who were registered for the first time at a tertiary institution before 2018 are subject to a maximum NSFAS amount for the year. The maximum NSFAS amount for 2020 is R93 400.
According to NSFAS policy, payments must be made in the following order of priority if your qualifying NSFAS costs exceed the maximum amount:
1. Tuition
2. Books
3. Accommodation
4. Meals
5. Transport
This means that the amount by which you exceeded the maximum NSFAS amount must be deducted from your allowances, starting with the transport and meal allowances. Therefore, you might not receive the full allowances.

How will NSFAS allowances be paid?

NSFAS allowances will be paid in cash to the student via the Fundi system. Once the allowances are debited to your student class-fee account, you will receive an SMS message from Fundi to upload your banking details. Fundi will confirm your banking details and payment will follow.

Please note that no payments will be made to a third party.
You only need to upload your banking details once. If you experience any problems with uploading your banking details, please contact Fundi at 086 055 5544.

When will I receive my NSFAS allowances?

NSFAS allowances will be paid during the first week of each month over a period of 10 months. Please note that due to several variables, a specific date for payment cannot be provided.

How do I apply for NSFAS private accommodation?

Please visit the UFS website for a complete guide:
Students
Financial Aid

When will I receive my private accommodation payment?

You must apply online for your private accommodation. It is compulsory to upload your rental agreement and proof of home address. If your private accommodation application is approved by the 25th of a month, you will receive payment from your move-in date up to date during the first week of the following month, and thereafter you will receive your monthly payments until November.

How will I know if my private accommodation application status has changed?

You will immediately receive an email on your ufs4life email address when your status changes.

What should I do if my private accommodation application is incomplete?

Please log in on your Student Self-Service. The reasons for your incomplete application will be listed under your private accommodation application. Please correct the application and resubmit. Please do not resubmit if the application was not corrected.
Please visit the website for clear explanations on the reasons for incomplete applications if you are unsure of what is expected of you.

Please note that no payment will be made before your private accommodation application is approved.

When is the closing date for NSFAS private accommodation applications?
The closing date for private accommodation applications is 11 September 2020. Please note that no extension will be granted.

News Archive

Nuclear Medicine on the forefront of cancer research

2017-07-10

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma. The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept